Elucid Adds Clinical and Commercial Leaders to its Executive Team

Elucid has added several senior members to its clinical and commercial teams as it prepares to commercially launch its U.S. Food and Drug Administration (FDA)-cleared PlaqueIQ image analysis software, which provides physicians with comprehensive patient, vessel and lesion-level plaque composition and quantification, and offers potential insights on heart attack/stroke risk prediction and personalized treatment decisions.

Amir Ahmadi, M.D., has joined Elucid as a chief scientific advisor and will lead the company’s clinical strategy.* Dr. Ahmadi is a cardiologist with a passion for advancing cardiovascular care through precision medicine, innovative research, and clinical excellence. He is a clinical associate professor of medicine (cardiology) at the Icahn School of Medicine at Mount Sinai in New York, N.Y., where he serves as director of Inpatient Cardiology and co-director of the Cardiac Intensive Care Unit (CICU) at Mount Sinai Morningside. Dr. Ahmadi’s clinical practice focuses on cardiac intensive care, multimodality imaging, and prevention cardiology of early atherosclerosis detection and personalized treatment. His ongoing clinical practice and research center on using computed tomography coronary angiography to detect and treat subclinical atherosclerosis, understand myocardial infarction mechanisms, and investigate the relationship between high-risk plaque features and ischemia.

Carol Holt, is now Elucid’s vice president of Clinical Development. She is an accomplished and multifaceted life sciences executive with deep expertise in clinical trial management, professional clinical education and business development for medical technologies including cardiovascular (heart failure) and interventional cardiology. Before joining Elucid, Holt served as vice president of Clinical Affairs for Ventric Health (formerly Avicena). She also held roles at Cerus Endovascular, which was acquired by Stryker Neurovascular in 2023, and Uptake Medical, which was acquired by Broncus in 2016. Before Holt’s startup experience, she spent 14 years with Edwards Lifesciences and seven years in CV ICU at the Texas Heart Institute.

Kevin Mathews has joined Elucid’s leadership team as senior vice president of Marketing. He is an experienced global commercial leader in the medical device space with more than 25 years of experience in segments including interventional cardiology, peripheral vascular, electrophysiology, and medical-surgical. Before joining Elucid in 2025, Mathews was the global commercial leader for Acutus, an arrhythmia mapping and ablation company. Prior to Acutus, Mathews held leadership roles in sales, marketing, and business development at Philips IGT Devices, a division created through Philips’ acquisitions of Volcano Corp and Spectranetics. He also held leadership roles at Jomed, DeRoyal, and in KPMG’s healthcare practice.

Amy Pyke is Elucid’s senior vice president of Market Access. She has 30 years of experience devising and implementing strategies and tactics to secure favorable reimbursement and coverage with commercial and government payors in medical device and pharmaceutical organizations across multiple therapeutic areas. Prior to joining Elucid, Pyke was head of Market Access and Reimbursement for IGTD & Systems at Philips. Previously, she led Stryker’s Instruments Market Access and Reimbursement Department and held a variety of market access and reimbursement positions at Edwards Lifesciences, GE Healthcare and Alcon.

“An experienced, diligent, and committed team is critical to any company’s success,” Elucid CEO Kelly Huang said. “With our clinical and commercial leaders in place, we can now accelerate progress towards our goal of a world where atherosclerosis can be routinely measured and treated on a patient-by-patient basis to prevent heart attack and stroke, ultimately saving lives.”

Atherosclerosis is a disease involving a series of histological changes to the arterial wall. Elucid’s PlaqueIQ is the first FDA-cleared non-invasive software that can objectively quantify and classify plaque morphology based on ground-truth histology, the gold standard for characterization of plaques. PlaqueIQ is designed to give physicians new, clinically validated information to help accurately diagnose and stratify patients, inform patient-specific treatment pathways, and potentially personalize treatment for cardiovascular disease.

On Jan. 1, 2025, a final rule from U.S. Centers for Medicare & Medicaid Services (CMS) went into effect that doubles the reimbursement for cardiac computed tomography angiography (CCTA), allowing more hospitals, particularly those in non-urban areas, to offer this service, reducing disparities in care. This reimbursement increase for CCTA followed recent decisions from five of the seven Medicare Administrative Contractors (MACs) to provide coverage for AI-enabled quantitative coronary plaque analysis, including PlaqueIQ, expanding accessibility to more than 70% of eligible Medicare patients across the United States.

Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company’s PlaqueIQ image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFRCT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively.

* Dr. Ahmadi has a financial relationship with Elucid in his role as chief scientific advisor.